This Menu contains links to pages related to Other topics. You can also see
- Menu: Treatments
- Menu: Mental disorders
- Menu: Side effects
- Menu: Laboratory testing
- Menu: Drug interactions
To use this Menu, please click on the category (or the arrow to the left of its name) to EXPAND the category and see what is included in it.
When you are done, click on the category (or the arrow to the left of it) to COLLAPSE the category back.
Evidence-Based Medicine (EBM)
Practice Guidelines
Available Practice Guidelines for Mental Disorders
Tips on using practice guidelines: When to use them. Where to find them. How to use them efficiently
Biostatistics
Clinicians’ guide to screening tests in mental health
Why cut-off scores on screening tests matter to clinicians
The Mood Disorders Questionnaire is being used inappropriately
Don’t use screening questionnaires for bipolar disorder
What is a p value? (video)
“No significant difference”: Not different, but not the same
An example of misleading means (averages)
Non-inferiority comparisons
What is Effect Size and how should it be interpreted?
Recommended books about EBM
Rating scales
Rating scales and questionnaires for mental health clinicians
Patient Health Questionnaire (PHQ-9)
Quick Inventory of Depressive Symptomatology (QIDS-SR)
Montgomery-Asberg Depression Rating Scale (MADRS)
Clinical Global Impressions Scale (CGI)
Scientific literature evaluation
Expert interviews
Audio
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Tips on neuroimaging to evaluate persons with dementia-Interview with Vimal Aga, MD on May 16, 2016
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Is tardive dyskinesia still a problem: Stanley Caroff, MD
Do second-generation antipsychotics have a lower risk of tardive dyskinesia: Stanley Caroff, MD
More on whether second-generation antipsychotics have a lower risk of tardive dyskinesia: Stanley Caroff, MD
Tips on how to identify tardive dyskinesia: Stanley Caroff, MD
What to do about the antipsychotic if the patient develops tardive dyskinesia: Stanley Caroff, MD
What to do about anticholinergics if tardive dyskinesia occurs: Stanley Caroff, MD
Valbenazine and deutrabenazine for tardive dyskinesia: Stanley Caroff, MD
Tips on managing akathisia: Stanley Caroff, MD
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Sexual dysfunction Part 1-Assessment: Anita Clayton, MD
Sexual dysfunction Part 2-Flibanserin: Anita Clayton, MD
Sexual dysfunction Part 3-Flibanserin & Bremelanotide: Anita Clayton, MD
Sexual dysfunction part 4-PDE-5 inhibitors & testosterone: Anita Clayton, MD
Sexual dysfunction part 5-Cyproheptadine & Yohimbine: Anita Clayton, MD
Sexual dysfunction part 6-CAM: Anita Clayton, MD
Sexual dysfunction part 7-How to identify it: Anita Clayton, MD
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Tips on assessing and managing suicidality: Interview with Jack Krasuski, MD on November 4, 2016
Click the link below to play.Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
14 Key Questions About Vilazodone-Part 1: Rajnish Mago, MD
14 Key Questions About Vilazodone-Part 2: Rajnish Mago, MD
14 Key Questions About Vilazodone-Part 3: Rajnish Mago, MD
14 Key Questions About Vilazodone-Part 4: Rajnish Mago, MD
14 Key Questions About Vilazodone-Part 5; Rajnish Mago, MD
14 Key Questions About Vilazodone-Part 6: Rajnish Mago, MD
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Tips on writing a letter at the termination of treatment-Rajnish Mago, MD
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
How to teach a powerful Relaxation Practice: Rajnish Mago, MD
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Part 1 of Psychodynamic psychopharmacology: Interview with David Mintz, MD on August 4, 2016
Part 2 of Psychodynamic psychopharmacology: Interview with David Mintz, MD on August 4, 2016
Part 3 of psychodynamic psychopharmacology: Interview with David Mintz, MD on August 4, 2016
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Transcranial magnetic stimulation (TMS): Interview with John O’Reardon, MD on September 10, 2016
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
Bipolar disorder: Interview with Gary Sachs, MD on September 29, 2016
Click the link below to play. Or, if you want to download the file to your own device, right-click on the link and choose “Save link as”
JAMA. this month had interesting article on AUD. They used WHO Criteria to study risk reduction and medication. Can you comment on any differences in the criteria and also on the issue of harm reduction versus abstention strategies? Thanks
Can you please comment on the evaluation and treatment of tic disorders?
Noted! Will do soon.
What is best clinical evidence to provide patients requesting medical approval for plasma donation ? I have been denying these requests. First d/t protein bound drugs that will be disrupted and second, the donation centers ask for excessive details pertaining to the patients mental health information: diagnosis, treatments, all medications, safety profile. The forms are long and cumbersome.
Thank you for your question. It has now been answered at this link: https://simpleandpractical.com/blood-plasma-donation-mental-health/
Hello Dr. Mago,
Your daily posts are worth more than what we are paying for.
Thanks
Pankaj Kishore MD
What do you recommend to patients with occasional migraines (head or gut) that are prescribed sumatriptan for intermittent use, while on an SSRI or SNRI? I have a patient prescribed an injectable 0.5 mg subcutaneous for cyclic vomiting syndrome, while on 75 mg BID of Effexor ER.She has been told Risks/Benefits and Alternatives and has been told about the signs and symptoms of serotonin syndrome. The question is, how do you know how much serotonin is too much serotonin before your patient is in trouble?
What do you think about the Proton Pump Inhibitors and Dementia? Are they linked? What is the risk?
Hi Alexa. Your question has now been answered at this link: https://simpleandpractical.com/proton-pump-inhibitors-cognitive-impairment-dementia/
What are the interactions between antibiotics and psychotropic medications?